IDEXX Laboratories, Inc. $IDXX Shares Bought by National Pension Service

National Pension Service boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 129,305 shares of the company’s stock after purchasing an additional 6,885 shares during the period. National Pension Service’s holdings in IDEXX Laboratories were worth $68,071,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. J.Safra Asset Management Corp acquired a new stake in shares of IDEXX Laboratories during the second quarter worth $25,000. SHP Wealth Management acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at $26,000. Elevation Wealth Partners LLC raised its stake in IDEXX Laboratories by 188.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after acquiring an additional 32 shares during the last quarter. Virtus Advisers LLC acquired a new stake in IDEXX Laboratories during the 3rd quarter worth about $26,000. Finally, WealthCollab LLC acquired a new stake in IDEXX Laboratories during the 2nd quarter worth about $30,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Citigroup increased their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. Barclays decreased their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, UBS Group increased their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $747.00.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the transaction, the director directly owned 9,568 shares in the company, valued at $5,090,941.44. The trade was a 18.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.79% of the stock is currently owned by company insiders.

IDEXX Laboratories Stock Down 0.4%

Shares of IDXX opened at $504.70 on Friday. The company has a market capitalization of $39.76 billion, a price-to-earnings ratio of 35.49, a PEG ratio of 2.70 and a beta of 1.54. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98. The stock’s 50-day moving average price is $555.59 and its 200-day moving average price is $566.45. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. During the same period last year, the business earned $3.50 earnings per share. IDEXX Laboratories’s quarterly revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.